Physician profile
Ann Dys
NPI 1710908884
$2,721.96
in general payments reported to CMS, 2019-2025
17 companies · $741 in 2025
The $741 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $161 · 2022: $489 · 2023: $669 · 2024: $662 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,072.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $464.23 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $266.10 | 2023-2024 | Spravato |
| Novo Nordisk INC | $249.99 | 2022-2023 | Wegovy |
| Neurelis, INC. | $200.09 | 2021-2025 | Valtoco |
| Axsome Therapeutics, INC. | $189.89 | 2024-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $167.95 | 2022-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Sanofi Pasteur INC. | $159.95 | 2022-2024 | |
| Ucb, INC. | $127.92 | 2025 | Rystiggo |
| Abbvie INC. | $124.20 | 2024 | |
| Idorsia Pharmaceuticals US INC | $117.21 | 2023 | Quviviq |
| Boston Scientific Corporation | $112.16 | 2025 | Wavewriter Alpha Prime 16 |
| Teva Pharmaceuticals USA, INC. | $105.12 | 2024 | Austedo Xr |
| Pfizer INC. | $99.94 | 2024 | |
| Jazz Pharmaceuticals INC. | $95.95 | 2022 | |
| Eisai INC. | $83.40 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $81.94 | 2021 | |
| Glaxosmithkline, LLC. | $75.92 | 2023-2024 | Bexsero, Pediarix, Menveo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Dys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.